DE69624699T2 - Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes - Google Patents

Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes

Info

Publication number
DE69624699T2
DE69624699T2 DE69624699T DE69624699T DE69624699T2 DE 69624699 T2 DE69624699 T2 DE 69624699T2 DE 69624699 T DE69624699 T DE 69624699T DE 69624699 T DE69624699 T DE 69624699T DE 69624699 T2 DE69624699 T2 DE 69624699T2
Authority
DE
Germany
Prior art keywords
tripicolinate
chrome
diabetes
high dose
treating type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69624699T
Other languages
German (de)
English (en)
Other versions
DE69624699D1 (de
Inventor
F Mccarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Nutrition 21 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC
Application granted granted Critical
Publication of DE69624699D1 publication Critical patent/DE69624699D1/de
Publication of DE69624699T2 publication Critical patent/DE69624699T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69624699T 1995-05-12 1996-05-08 Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes Expired - Fee Related DE69624699T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,362 US6329361B1 (en) 1995-05-12 1995-05-12 High-dose chromic picolinate treatment of type II diabetes
PCT/US1996/006493 WO1996035421A1 (en) 1995-05-12 1996-05-08 High-dose chromic tripicolinate for the treatment of type ii diabetes

Publications (2)

Publication Number Publication Date
DE69624699D1 DE69624699D1 (de) 2002-12-12
DE69624699T2 true DE69624699T2 (de) 2003-03-20

Family

ID=23748461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624699T Expired - Fee Related DE69624699T2 (de) 1995-05-12 1996-05-08 Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes

Country Status (15)

Country Link
US (1) US6329361B1 (es)
EP (1) EP0825861B1 (es)
JP (1) JP3699124B2 (es)
AR (1) AR004486A1 (es)
AT (1) ATE227127T1 (es)
AU (1) AU5733796A (es)
BR (1) BR9608835A (es)
DE (1) DE69624699T2 (es)
DK (1) DK0825861T3 (es)
ES (1) ES2183952T3 (es)
IL (1) IL118222A (es)
PT (1) PT825861E (es)
RU (1) RU2195934C2 (es)
WO (1) WO1996035421A1 (es)
ZA (1) ZA963735B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
JP2001513506A (ja) * 1997-08-08 2001-09-04 ニュートリション ２１ タイプｉｉ糖尿病のクロム／ビオチン治療
EP0925790A1 (en) * 1997-12-17 1999-06-30 Kartar Dr. Lalvani Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM)
US5932258A (en) * 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6143301A (en) 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5905075A (en) * 1998-08-28 1999-05-18 Ambi Inc. Chromium nicotinate compositions and uses thereof
EP1113804A2 (en) 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
DE60104450T2 (de) 2000-09-21 2005-09-15 Nutrition 21, Inc. Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils
US20050214384A1 (en) * 2002-04-23 2005-09-29 Vijaya Juturu Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
DE60333628D1 (de) * 2002-05-14 2010-09-16 Nipro Corp Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
CA3021932C (en) * 2007-01-31 2020-12-15 Jds Therapeutics, Llc Use of chromium histidinate for treatment of cardiometabolic disorders
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2448412B1 (en) 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
EP2680861B1 (en) 2011-03-01 2022-05-04 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2016130981A1 (en) 2015-02-13 2016-08-18 Mars, Incorporated Pet food feeding system
EP3413900A1 (en) 2016-02-11 2018-12-19 Nutrition 21, LLC Chromium containing compositions for improving health and fitness
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5164384A (en) 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula

Also Published As

Publication number Publication date
RU2195934C2 (ru) 2003-01-10
ATE227127T1 (de) 2002-11-15
JPH11504941A (ja) 1999-05-11
EP0825861B1 (en) 2002-11-06
AR004486A1 (es) 1998-12-16
DK0825861T3 (da) 2003-03-03
ES2183952T3 (es) 2003-04-01
MX9708628A (es) 1998-06-28
AU5733796A (en) 1996-11-29
BR9608835A (pt) 1999-12-07
PT825861E (pt) 2003-03-31
ZA963735B (en) 1997-01-09
EP0825861A1 (en) 1998-03-04
JP3699124B2 (ja) 2005-09-28
WO1996035421A1 (en) 1996-11-14
DE69624699D1 (de) 2002-12-12
US6329361B1 (en) 2001-12-11
IL118222A0 (en) 1996-09-12
IL118222A (en) 2000-06-01

Similar Documents

Publication Publication Date Title
DE69624699T2 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE69427869T2 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69612649T2 (de) Indolinonverbindungen zur behandlung von krankheiten
DE69710095T2 (de) Pharmazeutische zubereitung zur behandlung von diabetes
DE69609868T2 (de) Neue steroidester zur behandlung von hauterkrankungen
DE68907909D1 (de) Praeparat zur behandlung von erektionsstoerungen.
DE122007000002I1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
DE69525473D1 (de) Vorrichtung zur behandlung von blutgefässen
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69421196T2 (de) Vorrichtung zur behandlung von überbiss
DE69527140D1 (de) Wirkstoff zur prävention oder behandlung von osteoporose
DE69433793D1 (de) Phosphorderivate zur behandlung von aids
DE69721756D1 (de) Paroxetine zur behandlung von depression
DE69407992T2 (de) Kompakte pfanne zur behandlung von metallschmelze
DE990441T1 (de) Arzneimittel zur behandlung von diabetischer nephrosis
DE69130049D1 (de) Vorrichtung zur Behandlung von lichtempfindlichen Materialien
DE69515568T2 (de) Vorrichtung zur Behandlung von lichtempfindlichem Material
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
DE69812599D1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
DE69000960D1 (de) Zusammensetzung zur behandlung von pigmentierung.
DE69306260D1 (de) Behandlung von abwasser
DE59503643D1 (de) Vorrichtung zur behandlung von wertstoffgemischen
DE59911556D1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
DE29715637U1 (de) Vorrichtung zur Behandlung von körnigem Gut

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee